Claude-skill-registry-data ml-nmr-methodology
Deep methodology knowledge for ML-NMR including IPD/AgD integration, population adjustment, numerical integration, and prediction to target populations. Use when conducting or reviewing ML-NMR analyses.
git clone https://github.com/majiayu000/claude-skill-registry-data
T=$(mktemp -d) && git clone --depth=1 https://github.com/majiayu000/claude-skill-registry-data "$T" && mkdir -p ~/.claude/skills && cp -r "$T/data/ml-nmr-methodology" ~/.claude/skills/majiayu000-claude-skill-registry-data-ml-nmr-methodology && rm -rf "$T"
data/ml-nmr-methodology/SKILL.mdML-NMR Methodology
Comprehensive methodological guidance for conducting rigorous Multilevel Network Meta-Regression following NICE DSU guidance and multinma package documentation.
When to Use This Skill
- Deciding whether ML-NMR is appropriate
- Setting up integration points for AgD
- Specifying priors and models
- Understanding marginal vs conditional effects
- Predicting to target populations
- Reviewing ML-NMR code or results
When to Use ML-NMR
ML-NMR is Appropriate When:
-
Network Structure
- Multiple treatments form (partial) network
- Some studies have IPD, others only AgD
- Want to leverage all available evidence
-
Population Differences
- Effect modifiers differ across populations
- Standard NMA transitivity violated
- Need population-adjusted estimates
-
Target Population
- Want predictions for specific population
- Different from any single trial population
- Policy-relevant population definition
ML-NMR vs Alternatives
| Scenario | Recommended Method |
|---|---|
| All AgD, similar populations | Standard NMA |
| All AgD, different populations | NMA meta-regression |
| IPD for one study, AgD for one | MAIC or STC |
| IPD + AgD network | ML-NMR |
| Disconnected with IPD | ML-NMR (with assumptions) |
Key Concepts
Individual-Level vs Study-Level
ML-NMR Models Both: ├── Individual-level (within IPD studies) │ - Patient-level outcomes │ - Patient-level covariates │ - Exact covariate-outcome relationships │ └── Study-level (for AgD studies) - Aggregate outcomes - Covariate summaries - Integration over covariate distribution
Population Adjustment
Problem: AgD studies provide aggregate summaries, but we need individual-level predictions.
Solution: Numerical integration over the AgD population's covariate distribution.
For AgD study: Expected outcome = ∫ f(outcome | covariates, treatment) × p(covariates) d(covariates) Where: - f(): Individual-level outcome model (from IPD) - p(): Covariate distribution in AgD population
Integration Points
What Are Integration Points?
Discrete approximation to the integral over AgD population:
# Specify covariate distribution add_integration( network, age = distr(qnorm, mean = 62, sd = 10), sex = distr(qbinom, prob = 0.55), n_int = 500 ) # Creates 500 "pseudo-individuals" sampled from # the specified covariate distribution
Choosing Number of Integration Points
| Complexity | n_int | Description |
|---|---|---|
| Simple | 100-200 | 1-2 covariates, linear effects |
| Moderate | 300-500 | 2-3 covariates, typical use |
| Complex | 500-1000 | Many covariates, interactions |
| Very complex | 1000+ | Nonlinear effects, many variables |
Best Practice: Test sensitivity to n_int by running with different values.
Specifying Distributions
# Continuous: Normal distribution age = distr(qnorm, mean = 62, sd = 10) # Binary: Bernoulli (using binomial with size=1) sex = distr(qbinom, prob = 0.55) # Categorical: Discrete distribution # May need special handling # Correlated covariates: Copula methods # More complex setup required
Model Specification
Regression Component
nma( network, regression = ~ age + sex + age:sex, # Covariate effects ... ) # Interprets as: # Linear predictor = trt_effect + β_age × age + β_sex × sex + β_age:sex × age × sex
Effect Modifier vs Prognostic Factor
In ML-NMR regression formula: ├── Effect modifiers: Interact with treatment │ - regression = ~ age │ - Creates age × treatment interaction │ └── Prognostic factors: Affect baseline risk only - Handled through study random effects - Or explicit prognostic regression
Prior Specification
nma( ..., prior_intercept = prior_normal(0, 10), # Baseline risk prior_trt = prior_normal(0, 5), # Treatment effects prior_reg = prior_normal(0, 2), # Regression coefficients prior_het = prior_half_normal(1) # Heterogeneity ) # Considerations: # - Scale depends on link function # - Log-odds: 2-3 is large effect # - Informative priors from Turner et al. for het
Marginal vs Conditional Effects
Conditional Effects
- Effect at specific covariate values
- "Effect for a 65-year-old male"
- Directly from model coefficients
Marginal (Population-Averaged) Effects
- Effect averaged over population
- "Average effect in UK population"
- Obtained via integration
# Predict to target population target <- data.frame( age = seq(50, 80, 5), sex = 0.5 # 50% male ) predictions <- predict(fit, newdata = target)
Why the Difference Matters
For non-collapsible effect measures (OR, HR):
- Marginal effect ≠ Average of conditional effects
- Must integrate properly over population
- ML-NMR handles this correctly
Consistency Assessment
Node-Splitting in ML-NMR
# Fit node-split model nodesplit_fit <- nma( network, consistency = "nodesplit", ... ) # Check for direct vs indirect disagreement summary(nodesplit_fit)
Interpretation with Population Adjustment
- Inconsistency could be due to true treatment effect heterogeneity
- Or due to population differences not captured
- Node-splitting should be done after population adjustment
Treatment Rankings
Posterior Rank Probabilities
rank_probs <- posterior_rank_probs(fit) # Returns probability matrix: # P(treatment j has rank r)
Interpretation Cautions
Same as standard NMA:
- Rankings have uncertainty
- Small effect differences → large rank uncertainty
- Consider clinical significance alongside ranks
Prediction to Target Population
Specifying Target Population
# Method 1: Point prediction target <- data.frame(age = 62, sex = 0.5) # Method 2: Distribution prediction # Provide many points representing target distribution target <- data.frame( age = rnorm(1000, 60, 12), sex = rbinom(1000, 1, 0.45) )
Types of Predictions
# Relative effects (log scale) predict(fit, type = "link") # Relative effects (natural scale) predict(fit, type = "response") # Absolute outcomes predict(fit, type = "response", baseline = ...)
Convergence Diagnostics
Essential Checks
# 1. Print summary (shows R-hat, ESS) print(fit) # 2. Trace plots plot(fit, pars = "d") # 3. R-hat should be < 1.05 # 4. ESS should be > 400 per parameter
Addressing Convergence Issues
- Increase iterations: More warmup/sampling
- Adjust adapt_delta: Higher (0.95, 0.99) for divergences
- Reparameterize: Different model specifications
- Informative priors: If posterior too diffuse
- Check data: Sparse comparisons cause issues
Reporting Requirements
Methods
- Network structure description
- IPD vs AgD studies identified
- Covariate selection for adjustment
- Integration point specification
- Prior specification with justification
- Target population definition
- Convergence criteria
Results
- Network diagram
- Convergence diagnostics (R-hat, ESS)
- Relative effects for all comparisons
- Treatment rankings with uncertainty
- Consistency assessment
- Predictions to target population
- Sensitivity analyses
Common Pitfalls
1. Insufficient Integration Points
- Results may be unstable
- Check sensitivity to n_int
- Increase until results stabilize
2. Ignoring Convergence
- Must check R-hat and ESS
- Divergent transitions indicate problems
- Don't trust results without convergence
3. Wrong Covariate Distributions
- Must match AgD population
- Extract from publications carefully
- Consider correlation between covariates
4. Misinterpreting Marginal Effects
- Non-collapsible measures need care
- OR/HR: Marginal ≠ conditional
- Use predict() for proper marginalization
5. Not Specifying Target Population
- Default may not be policy-relevant
- Explicitly define target
- Sensitivity to target specification
Quick Reference Code
library(multinma) # 1. Set up IPD studies ipd_net <- set_ipd(ipd_data, study = study, trt = treatment, r = response) # 2. Set up AgD studies agd_net <- set_agd_arm(agd_data, study = study, trt = treatment, r = responders, n = sampleSize) # 3. Combine network network <- combine_network(ipd_net, agd_net) # 4. Add integration points network <- add_integration( network, age = distr(qnorm, mean = age_mean, sd = age_sd), sex = distr(qbinom, prob = sex_prop), n_int = 500 ) # 5. Fit ML-NMR fit <- nma( network, trt_effects = "random", regression = ~ age + sex, prior_intercept = prior_normal(0, 10), prior_trt = prior_normal(0, 5), prior_reg = prior_normal(0, 2), prior_het = prior_half_normal(1), adapt_delta = 0.95, chains = 4, iter = 4000, warmup = 2000, seed = 12345 ) # 6. Check convergence print(fit) # 7. Relative effects rel_eff <- relative_effects(fit) plot(rel_eff) # 8. Rankings ranks <- posterior_rank_probs(fit) plot(ranks) # 9. Predict to target target <- data.frame(age = 60, sex = 0.5) pred <- predict(fit, newdata = target) # 10. Node-splitting nodesplit_fit <- nma(network, consistency = "nodesplit", ...)
Resources
- NICE DSU TSD 18: Population-adjusted comparisons
- Phillippo et al. (2020): ML-NMR methods paper
- multinma package: https://dmphillippo.github.io/multinma/
- Stan User's Guide (for MCMC diagnostics)